Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records

Diabetes, Obesity and Metabolism

Volumn 18, Issue 9, 2016, Pages 916-924

  Zghebi, S S ^a,b   Steinke, D T ^a   Rutter, M K ^c,d   Emsley, R A ^a   Ashcroft, D M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF TRIPOLI   (Libyan Arab Jamahiriya)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cardiovascular disease; DPP 4 inhibitor; pharmaco epidemiology; sulphonylureas; thiazolidinediones; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SMOKING; SOCIAL STATUS; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS; AGED; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; INFORMATION RETRIEVAL; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; PROTECTION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INFORMATION STORAGE AND RETRIEVAL; MALE; METFORMIN; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED KINGDOM;

EID: 84977070620     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12692     Document Type: Article

References (40)

1. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians, 2008CG66. Available from URL: http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf. Accessed 22 July 2013.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
3. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryde'n L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008; 29: 166–176.
4. Raz I, Riddle MC, Rosenstock J et al. Personalized management of hyperglycemia in type 2 diabetes. Diabetes Care 2013; 36: 1779–1788.
5. Rutter MK, Nesto RW. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J 2011; 32: 2247–2255.
6. Hung Y-C, Lin C-C, Wang T-Y, Chang M-P, Sung F-C, Chen C-C. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2013; 29: 673–679.
7. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose- lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 4605–4612.
8. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013; 98: 668–677.
9. Hall GC, McMahon AD, Carroll D, Home PD. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose lowering therapy in people with type 2 diabetes: an observational study. Pharmacoepidemiol Drug Saf 2012; 21: 305–313.
10. Roumie CL, Hung AM, Greevy RA et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus. Ann Intern Med 2012; 157: 601–610.
11. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013; 346: f2267.
12. Seong J-M, Choi N-K, Shin JY et al. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. PLoS One 2015; 10: e0124287.
13. Ou S-M, Shih C-J, Chao P-W et al. effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 2015; 163: 663–672.
14. Herrett E, Gallagher AM, Bhaskaran K et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 44: 827–836.
15. Koro CE, Bowlin SJ, Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 2005; 14: 697–703.
16. Taylor KS, Heneghan CJ, Farmer AJ et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care 2013; 36: 2366–2371.
17. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014; 16: 977–983.
18. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract 2010; 60: e128–e136.
19. Springate DA, Kontopantelis E, Ashcroft DM et al. ClinicalCodes: an online clinical codes repository to improve the validity and reproducibility of research using electronic medical records. PLoS One 2014; 9: e99825.
20. Department for Communities and Local Government. The english indices of deprivation 2010. Crown, 2011. Available from URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/6871/1871208.pdf. Accessed 21 August 2013.
21. Lunt M. Propensity analysis in stata revision: 1.1. 2014. Available from URL: http://personalpages.manchester.ac.uk/staff/mark.lunt/propensity_guide.pdf. Accessed 1 July 2015.
22. Kontopantelis E. MIBMI: Stata Module for Cleaning and Multiple Imputation Algorithm for Body Mass Index (BMI) in Longitudinal Datasets. Boston College Department of Economics, 2015. Available from URL: https://ideas.repec.org/c/boc/bocode/s457972.html. Accessed 13 July 2015.
23. Herrett E, Shah AD, Boggon R et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 2013; 346: f2350.
24. Pantalone KM, Kattan MW, Yu C et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy. A retrospective analysis. Diabetes Care 2010; 33: 1224–1229.
25. Vallarino C, Perez A, Fusco G et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig 2013; 33: 621–631.
26. Corrao G, Romio SA, Zambon A, Merlino L, Bosi E, Scavini M. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol 2011; 67: 289–299.
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
28. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900–1908.
29. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
30. Evans JMM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930–936.
31. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865.
32. Levesque LE, Brophy JM, Aniello SD, Suissa S. Comparative cardiovascular morbidity and mortality of metformin in older adults with diabetes: a population-based cohort study. 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Brighton: Pharmacoepidemiology and Drug Safety, 2010: S2.
33. Waller DG, Renwick AG, Hillier K. Medical Pharmacology and Therapeutics. 3rd edn. Edinburgh: Elsevier, 2010.
34. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004; 20: 239–245.
35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471.
36. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.
37. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–242.
38. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326.
39. Johansen OE, Neubacher D, von Eynatten M, Patel S. Cardiovascular safety with linagliptin in patients with type 2 diabetes: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
40. Nathan DM, Buse JB, Kahn SE et al. Rationale and design of the Glycemia Reduction Approaches in Diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013; 36: 2254–2261.